Carmen Anthony Puliafito (born 1951) was an American ophthalmologist and academic administrator. From 2007 until March 2016, he was dean of the Keck School of Medicine of USC. In 2017, the Los Angeles Times revealed that Puliafito had engaged in parties with young recreational drug users and prostitutes, including at the Keck School's offices, and that Puliafito had smoked methamphetamine at these events. Early life and education Born and raised Buffalo, New York, Puliafito received a Bachelor of Arts degree from Harvard College in 1973 and a Doctor of Medicine from Harvard Medical School in 1978. He completed a residency in ophthalmology and a fellowship in vitreoretinal surgery at the Massachusetts Eye and Ear Infirmary. Puliafito also earned an MBA from the Wharton School of the University of Pennsylvania. Career Puliafito was appointed dean of the Keck School of Medicine of USC in December 2007. Before that, he had been director of the Bascom Palmer Eye Institute of the Leonard M. Miller School of Medicine, and chair of the department of ophthalmology. The institute has regularly been ranked as the best eye hospital and vision research center in the nation by U.S. News & World Report. In 2012, he was 21st of the highest-paid research university executives in the United States. While dean, he served on the board of the Children's Hospital Los Angeles. In March 2016, Puliafito resigned as dean of the Keck School of Medicine, and USC professor Rohit Varma was appointed interim dean. After leaving USC, he took a role as chief of strategic development with a pharmaceutical company called Ophthotech that was developing new drugs for eye diseases; he was laid off along with 80% of the staff in December 2016 when two phase III clinical trials produced negative results. Puliafito's California medical license was revoked based on disciplinary orders on August 17, 2018. Research Puliafito was one of the inventors of optical coherence tomography; for this work, James Fujimoto, Eric Swanson and Puliafito received a Rank Prize for Opto-Electronics in 2002. In 2012, Fujimoto, Swanson, and David Huang, with Puliafito and Joel Schuman, received an António Champalimaud Vision Award from the Champalimaud Foundation. Puliafito participated in research into the use of bevacizumab for the treatment of retinal disorders. 2017 Los Angeles Times report The Los Angeles Times reported in July 2017 that while Puliafito served as dean and USC professor, he "kept company with a